Glycoprotein G enables HSV-2 neuroinvasion and provides protection as a glycosylated vaccine antigen
Ebba SamuelssoniD, Carolina Gustafsson, Lindvi Gudmundsdotter, Ekaterina MirgorodskayaiD, Jonas Nilsson, Maria Ekblad, Beata Adamiak, Eva JennischeiD, Stefan LangeiD, Edward TrybalaiD, Staffan Görander, Tomas B. BergströmiD, Jan‐Åke LiljeqvistiD, Rickard NordéniD
Abstract
The function of glycoprotein G (gG-2) of herpes simplex virus 2 (HSV-2) during genital infection is unknown. gG-2 is cleaved into a secreted variant (sgG-2) and a membrane associated variant (mgG-2). This work delineates the glycan profile of mgG-2, and demonstrates that mgG-2 is strongly immunogenic, eliciting glycan dependent humoral and Th1-polarized CD4+ T cell responses in a mouse vaccination model. The N- and O-glycosylation of mgG-2 is important to achieve full protection against HSV-2 infection as immunization with deglycosylated mgG-2 resulted in poor CD4+ T cell activation and viral spread to dorsal root ganglia and spinal cord. Furthermore, an mgG-2 negative HSV-2 mutant virus failed to spread to the dorsal root ganglia and the central nervous system of genitally infected mice, despite viral replication in vaginal cells. Our data demonstrate that mgG-2 is important for HSV-2 propagation and that adaptive immune responses targeting the glycosylated protein can prevent neuronal infection, identifying mgG-2 as a promising vaccine candidate.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- FWCI
- 0.00
- Field percentile
- 49th percentile
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Immunization With Herpes Simplex Virus Nanoparticles Targeting Both Attachment and Fusion Protect Against Infection
Dawid Maciorowski, Alexander C Vostal, … Jeffrey I. Cohen·bioRxiv·Apr 29, 2026
- Structure-based design of soluble prefusion-stabilized herpes simplex virus type 2 glycoprotein B antigens
Madeline R. Sponholtz, Daphne Ma, … Jason S. McLellan·Cell ReportsPeer-reviewed·Sep 1, 2026
- Dual Impacts of a Glycan Shield on the Envelope Glycoprotein B of HSV-1: Evasion from Human Antibodies In Vivo and Neurovirulence
A. Fukui, Y. Maruzuru, … Y. Kawaguchi·bioRxiv·Dec 12, 2022
- Prefusion-specific glycoprotein B human antibodies protect against neonatal HSV-2 infection
Parastoo Amlashi, 김정렬, … Ivelin S. Georgiev·bioRxiv·Mar 26, 2026
- Antibodies targeting HSV glycoprotein B require effector functions to protect neonatal mice
Matthew D. Slein, Lesle M Jimenez, … Margaret E. Ackerman·Journal of VirologyPeer-reviewed·Mar 9, 2026
- Therapeutic Prime/Pull Vaccination of HSV-2 Infected Guinea Pigs with the Ribonucleotide Reductase 2 (RR2) Protein and CXCL11 Chemokine Boosts Antiviral Local Tissue-Resident and Effector Memory CD4+ and CD8+ T Cells and Protects Against Recurrent Genital Herpes
L. BenMohamed, A. Quadiri, … H. Schaefer·bioRxiv·Aug 8, 2023